EC approves Alnylams Givlaari for acute hepatic porphyria

The EC has approved Alnylam's Givlaari for adults and adolescents with acute hepatic porphyria. Givlaari was previously granted priority medicines designation by the European Medicines Agency...

Coronavirus Drug Development Update from NanoViricides, Inc.

NanoViricides is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19.

Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement

Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation announced they have entered into a licensing...

Nurix raises $120m financing to advance its protein modulation pipeline

Nurix has closed its funding round with a total of $120m. The financing was led by Foresite Capital and supported by new investors Bain Capital Life Sciences, Boxer Capital, EcoR1 Capital, Redmile Group...

Predictive oncology to launch AI drug discovery platform for Covid-19

Predictive Oncology has announced plans to launch an AI technology platform for vaccine and drug development under an operating agreement with Soluble...

Alembic Pharma receives 4 observations from USFDA for Panelav facility

Alembic Pharmaceuticals on Monday said that US health regulator has conducted an inspection at it Panelav facility in Gujarat and issued Form 483...